Mounjaro

• Mounjaro (generic: tirzepatide) is an injectable prescription medicine developed by Eli Lilly and Company
• Designed for adults with overweight/obesity (e.g., BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbid conditions) in the Indian market, with adjunct application for weight/obesity-related metabolic health. 
• It is unique in that it targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors — offering a dual-pathway approach to improve glycaemic control and reduce body weight/associated fat mass.
• Mounjaro improves blood sugar control in adults with type 2 diabetes when used in conjunction with a balanced diet and regular exercise. It aids in weight loss for obese (BMI ≥30) or overweight (BMI 27 and <30) adults by increasing insulin sensitivity and reducing hunger.

• Adults with Type 2 Diabetes — Tirzepatide Mounjaro® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D.
• Adults with Obesity/Overweight + Comorbidity — Tirzepatide is approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition (e.g., hypertension, dyslipidaemia, T2D, OSA, CVD), alongside reduced-calorie diet and increased physical activity.
• India access — Tirzepatide (Mounjaro KwikPen) has been cleared in India; regulators recommended/approved import & marketing, and recent notices report use for T2D and chronic weight management in adults meeting BMI criteria under prescription.
• Use conditions & exclusions (labels) — Prescription-only; must be combined with diet and activity; not for Type 1 diabetes. Clinicians screen for contraindications (e.g., MTC/MEN2 boxed warning).

 According to the Indian product listing for Eli Lilly:

• Generic Name: Tirzepatide
• Adult titration (typical):
  2.5 mg/0.6 mL, 5 mg/0.6 mL, 7.5 mg/0.6 mL, 10 mg/0.6 mL, 12.5 mg/0.6 mL, 15 mg/0.6 mL (in multiple-dose pre-filled pen) plus earlier single-dose vial versions (2.5 mg and 5 mg) listed.
• For each patient the exact dosage/titration must be personalised by the prescribing physician as part of the full care programme (your coaching model supports this).

‍

• Once-weekly injectable: designed for convenience compared to daily injections.
• Dual hormone receptor action (GIP + GLP-1) → improved insulin secretion, suppressed glucagon, delayed gastric emptying, increased fullness. 
• Real-world market uptake is strong: e.g., Mounjaro since its launch in March went on to become the 2nd best-selling drug in India within 6 months as on Sep 2025 showing early adoption  and explosive nature of the medicine

• Do not use if you or your family have had medullary thyroid carcinoma (MTC) or if you have the condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 
• Potential serious side-effects include: thyroid tumours, pancreatitis, gallbladder disease, hypoglycaemia (especially when used with insulin/insulin secretagogues), gastrointestinal reactions (nausea/constipation/vomiting). ‍
• It is not known if Mounjaro is safe and effective in children (under 18) in India.
• Must be used under physician supervision, within a holistic clinico-lifestyle framework (diet + exercise + monitoring).
• Emphasise that medication is one part of the programme — sustainable change requires integration with your diet, movement, coaching & monitoring ecosystem (which your startup is precisely well-placed to deliver).

• A medically-led screening process (to assess eligibility, contraindications, metabolic baseline)
• Custom nutritional plans (that align with weight-loss + metabolic optimisation)
• Movement science & progressive training protocols (especially important given your movement-rehab background)
• Weekly coaching check-ins, tracking transformation, tutor behavioural change, ensure adherence, manage side‐effects
• Step-down/transition strategy: as patients improve, tapering/maintenance options, long-term lifestyle sustainability

‍